Neal Shore, MD, Carolina Urologic Research Center

Highlights of potential future applications of PSMA ligand–directed therapies in prostate cancer.

Results of the phase 3 VISION study of 177Lu-PSMA PET in advanced prostate cancer are described.

Dr Neal Shore explains the clinical implications of PSMA PET scans in advanced prostate cancer.

An overview of the diagnostic and therapeutic applications of PSMA in prostate cancer is presented.

A discussion of phenotypic and genotypic biomarkers found in prostate cancer and their implications.

Neal Shore, MD, discusses the complexity of prostrate cancer and factors to consider when determining management strategies.

Neal Shore, MD, presents data on the tolerability of and responses to darolutamide (DARO) as seen in the extended follow-up of the phase 3 ARAMIS trial of DARO treatment in men with high-risk, nonmetastatic, castration-resistant prostate cancer. The results were reported at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Neal Shore, MD, presents data on treatment preferences from the phase 2 ODENZA trial of darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer. The results were reported at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

Experts discuss challenges and unmet needs in men with advanced prostate cancer who are undergoing treatment with androgen deprivation therapy.

Stephen Freedland, MD, discusses risk factors involved in men with advanced prostate cancer who receive androgen deprivation therapy.

Dan George, MD, reviews new findings in advanced prostate cancer presented at ASCO GU 2021.

Neal Shore, MD, discusses the recent FDA approval of the first oral GNRH receptor antagonist, relugolix, for men with advanced prostate cancer, along with data from the phase 3 HERO trial.